CIMEIO THERAPEUTICS
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.
CIMEIO THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2020-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.cimeio.com
Total Employee:
11+
Status:
Active
Contact:
+41 61 577 2316
Email Addresses:
[email protected]
Total Funding:
50 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Global Site Tag Mobile Non Scaleable Content Organization Schema Google Maps
Current Advisors List
Investors List
Versant Ventures
Versant Ventures investment in Series A - Cimeio Therapeutics
Official Site Inspections
http://www.cimeio.com
- Host name: ip72.ip-51-77-75.eu
- IP address: 51.77.75.72
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Cimeio Therapeutics"
About Us - Cimeio Therapeutics
Cimeio is a therapeutics company developing Shielded-Cell & Immunotherapy Pairsâ„¢ (SCIP), novel immunotherapies which have the potential to transform treatment of hematologic …See details»
Cimeio Therapeutics - Crunchbase Company Profile & Funding
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders. The technology platform developed by …See details»
Versant Ventures Launches Cimeio Therapeutics with $50 Million …
Cimeio Therapeutics - LinkedIn
Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening ...See details»
Cimeio Company Profile 2024: Valuation, Funding & Investors
When was Cimeio founded? Cimeio was founded in 2020. Where is Cimeio headquartered? Cimeio is headquartered in Cambridge, MA. What is the size of Cimeio? Cimeio has 28 total …See details»
$50 Million Series A - versantventures.com
Versant Ventures Launches Cimeio Therapeutics wit h $50 Million Series A — N ove l c e l l t h e ra py c o m pa ny l a u n c h e d o u t o f Ve r s a n t ’s R i d ge l i n e D i s c ove r y E n gi n e —See details»
Cimeio exits stealth with $50M, but its cell therapy …
Apr 13, 2022 Novel cell therapy company Cimeio Therapeutics is exiting stealth mode—though its science isn’t. The Versant Ventures-backed company has publicly entered the industry with a $50 million series ...See details»
Cell therapy meets the very latest in gene editing: start-up Cimeio ...
Jun 26, 2023 Gentler cell therapies for blood cancer and other serious blood diseases – this is the goal that Cimeio Therapeutics, a University of Basel spin-off, has set itself. The start-up …See details»
Cimeio Therapeutics - VentureRadar
Cimeio is an applied gene editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairsâ„¢ (SCIP), which has the potential to transform …See details»
Cimeio Company Profile - Office Locations, Competitors, Revenue …
Cimeio has 5 employees at their 1 location and $50 m in total funding,. See insights on Cimeio including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Success story Cimeio - BaseLaunch
Cimeio is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. …See details»
Versant Ventures Launches Cimeio Therapeutics with $50 Million …
Apr 13, 2022 Cimeio’s shielding technology was discovered and developed in the labs of founder Lukas Jeker, M.D., Ph.D., Professor at the Department of Biomedicine, University of …See details»
Cimeio Therapeutics Announces Issuance of Key Patent Covering …
Nov 28, 2022 Cimeio is an applied gene editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs® (SCIP), which has the potential to …See details»
Cimeio Therapeutics Wins $50M to Power Cell-Shielding Technology
Apr 12, 2022 Cimeio Therapeutics, a novel cell therapy startup, announced the completion of a $50 million Series A financing round Wednesday morning. The funding, led by Versant …See details»
Cimeio Therapeutics AG — RIDGELINE Discovery
Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs(tm) for patients with debilitating and life …See details»
Cimeio Therapeutics Therapy Platform Featured in Forbes Article
Aug 20, 2024 Cimeio Therapeutics is thrilled to announce that our therapy platform has been featured in a recent Forbes article, highlighting our groundbreaking work in blood cancer …See details»
Cimeio Therapeutics receives USD 50 million to advance new …
Apr 13, 2022 Versant Ventures has made a $50 million Series A commitment to Cimeio, which is the most recent start-up to emerge from the firm’s Ridgeline Discovery Engine in Basel, …See details»
Cimeio Therapeutics Announces Publication in - Business Wire
May 22, 2024 Cimeio is an immunotherapy company developing Shielded-Cell & Immunotherapy Pairsâ„¢ (SCIP), novel immunotherapies which have the potential to transform …See details»
Publications - Cimeio Therapeutics
May 31, 2023 Get the latest published data by Cimeio Therapeutics, an applied gene editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairsâ„¢ …See details»